[Form 4] Royalty Pharma plc Insider Trading Activity

Rhea-AI Filing Summary

Royalty Pharma plc EVP & CFO Terrance P. Coyne reported open-market sales of Class A Ordinary Shares of Royalty Pharma plc (RPRX) on 11/17/2025. The transactions, made under a Rule 10b5-1 trading plan adopted on August 8, 2025, included the sale of 65,844 Class A Ordinary Shares by TPC RP 2021, LLC at a weighted average price of $39.3041 per share and 3,750 Class A Ordinary Shares by TPC RP EPA1 LLC at a weighted average price of $39.304 per share.

Following these trades, the filing reports 724,156 Class A Ordinary Shares held indirectly through TPC RP 2021, LLC and 54,760 Class A Ordinary Shares held indirectly through TPC RP EPA1 LLC, along with additional indirect and direct holdings through IRAs, a spouse’s IRA, and personal accounts. The filing also notes limited partnership interests exchangeable into 6,448,180 Class A Ordinary Shares and ownership of 1,807,277 Class E Ordinary Shares of Royalty Pharma Holdings Ltd that may convert into an equivalent number of Class A Ordinary Shares upon vesting.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Coyne Terrance P.

(Last) (First) (Middle)

C/O ROYALTY PHARMA PLC

110 EAST 59TH STREET

(Street)

NEW YORK NY 10022

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Royalty Pharma plc [ RPRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP & CFO

3. Date of Earliest Transaction (Month/Day/Year)
11/17/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Class A Ordinary Shares	11/17/2025		S(1)		65,844	D	$39.3041(2)	724,156	I	By TPC RP 2021, LLC
Class A Ordinary Shares	11/17/2025		S(1)		3,750	D	$39.304(2)	54,760	I	TPC RP EPA1 LLC
Class A Ordinary Shares								24,170	I	By Spouse's IRA
Class A Ordinary Shares								23,270	I	By IRA
Class A Ordinary Shares								1,500	D
Class A Ordinary Shares								1,450	I	By Spouse

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. All reported transactions were effected pursuant to a 10b5-1 plan adopted by the Reporting Person on August 8, 2025.

2. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.97 to $39.50 per share. The holder undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Remarks:

In addition to the holdings of Class A Ordinary Shares disclosed above, the Reporting Person and family vehicles controlled by the Reporting Person hold limited partnership interests in RPI US Partners 2019, LP that are exchangeable into 6,448,180 Class A Ordinary Shares. The Reporting Person also holds 1,807,277 Class E Ordinary Shares of Royalty Pharma Holdings Ltd, certain of which are subject to vesting conditions and may, upon vesting, be converted into an equivalent number of Class A Ordinary Shares.

	/s/ Sean Weisberg, as Attorney-in-Fact for Terrance P. Coyne	11/19/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Royalty Pharma (RPRX) report in this Form 4?

The Form 4 reports that EVP & CFO Terrance P. Coyne sold 65,844 Class A Ordinary Shares indirectly through TPC RP 2021, LLC and 3,750 Class A Ordinary Shares indirectly through TPC RP EPA1 LLC on 11/17/2025.

At what prices were the Royalty Pharma (RPRX) shares sold in the reported transactions?

The filing states weighted average sale prices of $39.3041 per share for the 65,844 shares sold through TPC RP 2021, LLC and $39.304 per share for the 3,750 shares sold through TPC RP EPA1 LLC, with individual trades ranging from $38.97 to $39.50 per share.

Was the Royalty Pharma (RPRX) CFO trading under a Rule 10b5-1 plan?

Yes. The filing explains that all reported transactions were effected under a Rule 10b5-1 trading plan adopted by the reporting person on August 8, 2025.

How many Royalty Pharma (RPRX) Class A shares does the reporting person beneficially own after the Form 4 transactions?

After the reported trades, the filing shows 724,156 Class A Ordinary Shares held indirectly through TPC RP 2021, LLC, 54,760 Class A Ordinary Shares indirectly through TPC RP EPA1 LLC, and additional holdings including 24,170 Class A Ordinary Shares in a spouse’s IRA, 23,270 Class A Ordinary Shares in an IRA, 1,500 Class A Ordinary Shares held directly, and 1,450 Class A Ordinary Shares held by a spouse.

What other equity interests linked to Royalty Pharma (RPRX) are disclosed in the Form 4?

The filing notes that the reporting person and family vehicles hold limited partnership interests in RPI US Partners 2019, LP exchangeable into 6,448,180 Class A Ordinary Shares. It also reports ownership of 1,807,277 Class E Ordinary Shares of Royalty Pharma Holdings Ltd, certain of which are subject to vesting and may convert into an equivalent number of Class A Ordinary Shares.

What is the reporting person’s relationship to Royalty Pharma (RPRX)?

The reporting person is disclosed as an officer of Royalty Pharma plc, serving as EVP & CFO, and is filing the Form 4 as a single reporting person.